Avextra’s IMPACT study reveals that its Cannabis Extract 10:10 significantly improved sleep quality and reduced pain in chronic pain patients experiencing sleep disturbances. The 12-week study demonstrated improvements in sleep, pain reduction, and a decrease in the use of co-medications, particularly sleep and opioid medications. These findings were presented at the German Pain and Palliative Care Days.
This research is particularly relevant because it addresses the significant burden of chronic pain and sleep disorders, both of which contribute substantially to healthcare costs and reduced productivity. The study provides evidence for a potential new treatment option using a cannabinoid-based therapy, which could offer a much-needed alternative for patients who do not find relief with traditional medications. The observed reduction in opioid use is especially noteworthy, given the ongoing opioid crisis.
The IMPACT study demonstrated a 65% improvement in sleep quality among participants and a 44% clinically meaningful reduction in pain scores. The use of co-medications decreased by 30% overall, with sleep medication use dropping by almost 70% and opioid use declining by nearly 30%. The study also identified that fibromyalgia patients experienced greater improvements in sleep, while neuropathic pain patients reported better pain relief. Notably, the therapy was well-tolerated with no serious adverse events.
These positive results pave the way for further research into the long-term effects of cannabinoid-based therapies for pain and sleep management. This could lead to a shift in how these conditions are treated, potentially offering a safer and more effective alternative to traditional medications and contributing to improved patient outcomes and reduced reliance on potentially addictive drugs. The findings also suggest the potential for personalized treatment approaches based on specific pain conditions.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
